Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRN OTCMKTS:CHUC NASDAQ:DRUG NASDAQ:FDMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$15.01+0.3%$15.48$7.08▼$17.49$309.62M0.7752,947 shs45,523 shsCHUCCharlie's$0.30-4.5%$0.17$0.03▼$0.35$83.56M0.9235,685 shs359,971 shsDRUGBright Minds Biosciences$48.75-1.3%$36.45$0.94▼$79.02$347.83M-6.1468,790 shs80,383 shsFDMT4D Molecular Therapeutics$6.81-3.7%$5.70$2.23▼$17.41$330.19M2.86617,578 shs517,375 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin+0.27%-2.09%+0.07%+13.28%+27.66%CHUCCharlie's-4.52%+6.67%+78.82%+203.39%+245.45%DRUGBright Minds Biosciences-1.28%+15.41%+20.25%+76.76%+3,979.50%FDMT4D Molecular Therapeutics-3.68%-6.33%+2.10%+55.13%-56.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$15.01+0.3%$15.48$7.08▼$17.49$309.62M0.7752,947 shs45,523 shsCHUCCharlie's$0.30-4.5%$0.17$0.03▼$0.35$83.56M0.9235,685 shs359,971 shsDRUGBright Minds Biosciences$48.75-1.3%$36.45$0.94▼$79.02$347.83M-6.1468,790 shs80,383 shsFDMT4D Molecular Therapeutics$6.81-3.7%$5.70$2.23▼$17.41$330.19M2.86617,578 shs517,375 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin+0.27%-2.09%+0.07%+13.28%+27.66%CHUCCharlie's-4.52%+6.67%+78.82%+203.39%+245.45%DRUGBright Minds Biosciences-1.28%+15.41%+20.25%+76.76%+3,979.50%FDMT4D Molecular Therapeutics-3.68%-6.33%+2.10%+55.13%-56.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 1.50Reduce$12.00-20.05% DownsideCHUCCharlie's 0.00N/AN/AN/ADRUGBright Minds Biosciences 3.11Buy$81.0066.15% UpsideFDMT4D Molecular Therapeutics 2.64Moderate Buy$30.40346.40% UpsideCurrent Analyst Ratings BreakdownLatest CHUC, AMRN, DRUG, and FDMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025DRUGBright Minds BiosciencesBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$72.008/30/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/25/2025AMRNAmarinZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/19/2025DRUGBright Minds BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$85.008/14/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/12/2025FDMT4D Molecular TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$44.00 ➝ $38.008/12/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/1/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.007/29/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating7/12/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating7/3/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$228.61M1.36N/AN/A$23.62 per share0.64CHUCCharlie's$8.49M9.40N/AN/A($0.01) per share-30.40DRUGBright Minds BiosciencesN/AN/AN/AN/A$0.92 per shareN/AFDMT4D Molecular Therapeutics$40K7,950.68N/AN/A$11.05 per share0.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$82.18M-$3.67N/AN/AN/A-47.22%-21.18%-15.00%10/29/2025 (Estimated)CHUCCharlie's-$4.16M$0.0130.43∞N/A19.36%-174.49%36.91%11/17/2025 (Estimated)DRUGBright Minds Biosciences-$2.06M-$0.93N/AN/AN/AN/A-20.96%-20.66%N/AFDMT4D Molecular Therapeutics-$160.87M-$3.53N/AN/AN/A-594,375.81%-40.15%-36.43%11/12/2025 (Estimated)Latest CHUC, AMRN, DRUG, and FDMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2025Q2 2025CHUCCharlie'sN/A$0.02N/A$0.02N/A$2.54 million8/14/2025Q3 2025DRUGBright Minds Biosciences-$0.59-$0.53+$0.06-$0.53N/AN/A8/11/2025Q2 2025FDMT4D Molecular Therapeutics-$0.88-$0.98-$0.10-$0.98$0.52 million$0.01 million7/30/2025Q2 2025AMRNAmarin-$0.66-$0.03+$0.63-$0.03$45.45 million$72.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/ACHUCCharlie'sN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.262.34CHUCCharlie's0.071.610.61DRUGBright Minds BiosciencesN/A86.6486.64FDMT4D Molecular TherapeuticsN/A8.758.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%CHUCCharlie's7.80%DRUGBright Minds Biosciences40.52%FDMT4D Molecular Therapeutics99.27%Insider OwnershipCompanyInsider OwnershipAMRNAmarin3.30%CHUCCharlie's20.90%DRUGBright Minds Biosciences42.66%FDMT4D Molecular Therapeutics9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.68 million20.00 millionOptionableCHUCCharlie's40262.43 million207.59 millionNot OptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableFDMT4D Molecular Therapeutics12046.70 million42.22 millionOptionableCHUC, AMRN, DRUG, and FDMT HeadlinesRecent News About These Companies4DMT Announces New Employment Inducement GrantsSeptember 12 at 4:05 PM | globenewswire.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $30.40 Consensus Target Price from AnalystsSeptember 11 at 2:47 AM | americanbankingnews.com4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 9, 2025 | seekingalpha.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 9, 2025 | marketbeat.com4D Molecular Therapeutics, Inc. $FDMT Shares Acquired by Invesco Ltd.September 8, 2025 | marketbeat.comNuveen LLC Invests $486,000 in 4D Molecular Therapeutics, Inc. $FDMTSeptember 7, 2025 | marketbeat.comBVF Inc. IL Grows Position in 4D Molecular Therapeutics, Inc. $FDMTSeptember 5, 2025 | marketbeat.comJim Cramer on 4D Molecular Therapeutics: “This is a Pure Spec”September 5, 2025 | insidermonkey.comRedmile Group LLC Sells 199,675 Shares of 4D Molecular Therapeutics, Inc. $FDMTSeptember 4, 2025 | marketbeat.comWellington Management Group LLP Purchases 70,192 Shares of 4D Molecular Therapeutics, Inc. $FDMTSeptember 3, 2025 | marketbeat.com4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA ReadinessSeptember 2, 2025 | globenewswire.com4D Molecular Therapeutics (NASDAQ:FDMT) Given "Sell (D-)" Rating at Weiss RatingsSeptember 1, 2025 | marketbeat.com4DMT to Participate in Upcoming Investor ConferencesAugust 25, 2025 | globenewswire.comFY2025 EPS Estimates for FDMT Decreased by Cantor FitzgeraldAugust 17, 2025 | marketbeat.comChardan Capital Has Weak Forecast for FDMT FY2025 EarningsAugust 17, 2025 | marketbeat.comHC Wainwright Brokers Lower Earnings Estimates for FDMTAugust 16, 2025 | marketbeat.comQ3 EPS Forecast for 4D Molecular Therapeutics Cut by AnalystAugust 16, 2025 | marketbeat.com4DMT Announces New Employment Inducement GrantsAugust 15, 2025 | globenewswire.comBrokers Offer Predictions for FDMT FY2027 EarningsAugust 15, 2025 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Rating of "Moderate Buy" by AnalystsAugust 15, 2025 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $38.00 by Analysts at Roth CapitalAugust 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 20253 Biotech Catalysts Present Major OpportunityBy Nathan Reiff | August 25, 2025JNJ Stock Surge Signals Confidence in New Growth PathBy Jeffrey Neal Johnson | August 25, 2025CHUC, AMRN, DRUG, and FDMT Company DescriptionsAmarin NASDAQ:AMRN$15.01 +0.04 (+0.27%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$14.99 -0.02 (-0.13%) As of 09/12/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Charlie's OTCMKTS:CHUC$0.30 -0.01 (-4.52%) As of 09/12/2025 03:38 PM EasternCharlie's Holdings, Inc., together with its subsidiaries, formulates, markets, and distributes non-combustible nicotine-related, alternative alkaloid vapor, and hemp-derived vapor and edible products. It sells its products through distributors, specialty retailers, and third-party online resellers in the United States, the United Kingdom, Italy, Spain, New Zealand, Australia, and Canada. Charlie's Holdings, Inc. was founded in 2014 and is headquartered in Costa Mesa, California.Bright Minds Biosciences NASDAQ:DRUG$48.75 -0.63 (-1.28%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$48.48 -0.27 (-0.56%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.4D Molecular Therapeutics NASDAQ:FDMT$6.81 -0.26 (-3.68%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$6.81 0.00 (0.00%) As of 09/12/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
